Potential Drug-Drug Interactions With Psilocybin, MDMA, Ketamine
October 21st 2021Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses potential drug-drug interactions with psilocybin, MDMA, and ketamine to consider outside of interactions with psychiatric medications.
Stand Up To Cancer, Jazz Pharmaceuticals Collaborate to Accelerate Drug Development
October 20th 2021In an interview with Pharmacy Times®, Lee Helman, MD, vice chair on Stand Up To Cancer's Scientific Advisory Committee, discusses the research collaboration between Stand Up To Cancer and Jazz Pharmaceuticals.
Social Media Campaign Aims to Raise Awareness, Create Change for Pharmacy Working Conditions
October 19th 2021The #PizzaIsNotWorking campaign originated because free pizza or other mundane incentives do not adequately address the unrealistic expectations in pharmacies, which lead to an emphasis on metrics rather than patient safety.
Expert: MDMA for the Treatment of PTSD May Be FDA-Approved by the End of 2023
October 19th 2021Ismail Lourido Ali, the director and counsel of policy and advocacy at the Multidisciplinary Association for Psychedelic Studies (MAPS), discusses what MAPS is, and how MAPS is engaged with the field of psychedelic medicine and its use in health care.
New Drugs and Clinical Pearls in the Community Setting
October 18th 2021Pezzino discussed new specific prescriptions and treatments compared to current treatment modalities, indications and routes of administration of new drugs in the community setting, and important pharmacokinetic properties of these new drugs.
The FDA Modernization Act of 2021 Aims to Use Alternatives to Animal Testing
October 15th 2021Aysha Akhtar, CEO and co-founder for the Center for Contemporary Sciences discusses the FDA Modernization Act of 2021, aiming to modernize the drug testing process by allowing the use of other testing methods as an alternative to animal testing.
Clinical Development Program Shows Promise for Microbiome-Based Therapeutics in Recurrent C. Diff
October 14th 2021Lindy Bancke, PharmD, head of clinical development at Rebiotix Inc, said the clinical development program of RBX2660 is showing promise in the treatment of recurrent C. Difficile infection.
Iowa's Drug Disposal Program Designed for Positive Impact on Opioid Epidemic
October 13th 2021In an interview with Pharmacy Times®, Mitchell Barnett, PharmD, MS, associate director of the Iowa Prescription Monitoring Program for the Iowa Board of Pharmacy, and Mylo Wells, PharmD, owner of Wells Hometown Drug, discuss Iowa’s new drug disposal kit program and the impact it could have on the opioid epidemic.
Prioritizing Patient Care, Safety Through Integrated Technology
October 12th 2021Pharmacy Times spoke with Dr. Jeffrey Akers, CEO of Pharmaceutical Services at Appalachian Regional Healthcare, about how integrated technology can empower pharmacists to prioritize patient care and safety and can help prevent harmful medication events from occurring.
Expert: Pfizer Requests the Approval of COVID-19 Vaccine for Ages 5 to 11
October 8th 2021Anna Legreid-Dopp, PharmD, Senior Director of Clinical Guidelines and Quality Improvement at the American Society of Health-System Pharmacists discusses Pfizer’s request to approve their COVID-19 vaccine for children 5 to 11.